×
About 19,652 results

ALLMedicine™ Sarcomas Center

Research & Reviews  9,453 results

Complications, mobility, and quality of life in ankle sarcoma patients.
https://doi.org/10.1302/0301-620X.103B3.BJJ-2020-1308.R1
The Bone & Joint Journal; Smolle MA, Leithner A et. al.

Mar 1st, 2021 - The aims of the study were to analyze differences in surgical and oncological outcomes, as well as quality of life (QoL) and function in patients with ankle sarcomas undergoing three forms of surgical treatment, minor or major limb salvage surgery...

Impact of NICE guidelines on the survival of patients with soft-tissue sarcomas.
https://doi.org/10.1302/0301-620X.103B3.BJJ-2020-0743.R1
The Bone & Joint Journal; Fujiwara T, Grimer RJ et. al.

Mar 1st, 2021 - Urgent referral to a specialist centre for patients with a soft-tissue sarcoma (STS) has been recommended by the National Institute for Health and Care Excellence (NICE) in the UK since 2006. However, the impact of this recommendation on the progn...

Cardiac Tamponade as an Unusual Initial Clinical Manifestation of CIC-DUX4 Sarcoma.
https://doi.org/10.12659/AJCR.929349
The American Journal of Case Reports; Maekawa A, Matsunobu T et. al.

Feb 28th, 2021 - BACKGROUND CIC-rearranged sarcoma (CRS) is a recently described subset of undifferentiated small-round-cell sarcomas of bone and soft tissue. DUX4 is the most common gene involved in CRS. CRS usually presents in the soft tissue of the trunk and ex...

What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and...
https://doi.org/10.1097/CORR.0000000000001681
Clinical Orthopaedics and Related Research; Aryal A, Kumar VS et. al.

Feb 26th, 2021 - Skeletal metastases of bone sarcomas are indicators of poor prognosis. Various imaging modalities are available for their identification, which include bone scan, positron emission tomography/CT scan, MRI, and bone marrow aspiration/biopsy. Howeve...

Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherap...
https://doi.org/10.1007/s12094-021-02559-z 10.1200/JCO.2002.20.3.776 10.1200/JCO.2003.08.165 10.1158/1078-0432.CCR-16-2349 10.1002/cncr.30738 10.1016/s1470-2045(17)30624-1 10.1001/jamaoncol.2017.1617 10.1073/pnas.0915174107 10.1158/2159-8290.CD-17-1417 10.1002/cncr.30606 10.1007/s12094-012-0795-1 10.1158/1078-0432.CCR-15-2550 10.1200/JCO.2014.58.0225 10.1007/s00262-015-1731-3 10.1158/1078-0432.CCR-14-2708 10.2217/imt-2017-0101 10.1056/NEJMoa1802357 10.1200/JCO.2015.64.8931 10.1056/NEJMoa1504627 10.1016/s0140-6736(18)31257-1 10.1158/2159-8290.CD-17-0593 10.1038/s41591-018-0321-2 10.1158/1535-7163.MCT-14-0983 10.1038/nature14011 10.1001/jamaoncol.2016.0639 10.1371/journal.pone.0052926 10.21873/anticanres.12933 10.1111/cas.13769 10.1016/j.jtho.2019.06.010 10.1016/s1470-2045(13)70585-0 10.1200/JCO.2008.18.0794 10.1056/NEJMoa1708566 10.1056/NEJMoa1611299 10.1016/s1470-2045(19)30626-6 10.1016/s1567-5769(01)00071-6 10.1186/1479-5876-5-67 10.1007/s10549-004-3289-1 10.3109/08923970903300151 10.4049/jimmunol.175.3.1586 10.1158/1078-0432.CCR-11-2941 10.1186/1471-230X-12-109 10.1371/journal.pone.0082870 10.7150/jca.18683 10.1038/85330 10.3389/fonc.2019.00047 10.1016/j.oraloncology.2019.01.015 10.1245/s10434-019-07231-z 10.1111/j.1349-7006.2006.00317.x 10.1002/jso.21829 10.1080/2162402X.2016.1278100
Clinical & Translational Oncology : Official Publication ... Miwa S, Nojima T et. al.

Feb 26th, 2021 - Although immunotherapy is thought to be a promising cancer treatment, most patients do not respond to immunotherapy. In this post hoc analysis of a phase 1/2 study, associations of programmed death ligand 1 (PD-L1), PD-L2, and HLA class I expressi...

see more →

Guidelines  33 results

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatme...
https://doi.org/10.1093/annonc/mdy310
Annals of Oncology : Official Journal of the European Soc... Casali PG, Bielack S et. al.

Oct 4th, 2018 - Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2018|Casali PG,Bielack S,Abecassis N,Aro HT,Bauer S,|methods,standards,standards,therapeutic use,diagnosis,epidemiology,pathology,therapy,diag...

Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment an...
https://academic.oup.com/annonc/article/29/Supplement_4/iv79/5115250
Casali, P

Sep 30th, 2018 - Primary bone tumours are rare, accounting for < 0. 2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care of cancer patients) database [1].

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagno...
https://doi.org/10.1093/annonc/mdy096
Annals of Oncology : Official Journal of the European Soc... Casali PG, Abecassis N et. al.

May 30th, 2018 - Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2018|Casali PG,Abecassis N,Aro HT,Bauer S,Biagini R,|methods,standards,standards,therapeutic use,diagnostic imaging,pathology,meth...

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, ...
https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy096/5004451
Casali, P. G.

May 27th, 2018 - Soft tissue sarcomas (STSs) gather over 80 histological entities, with even more molecular subsets, characterised by a low to very low incidence in all populations. The majority of sarcomas arise from the soft tissue (close to 75%), with ?15% gast.

Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/5/536.full
Mehren, M.

Apr 30th, 2018 - Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues.

see more →

Drugs  27 results see all →

Clinicaltrials.gov  9,803 results

Complications, mobility, and quality of life in ankle sarcoma patients.
https://doi.org/10.1302/0301-620X.103B3.BJJ-2020-1308.R1
The Bone & Joint Journal; Smolle MA, Leithner A et. al.

Mar 1st, 2021 - The aims of the study were to analyze differences in surgical and oncological outcomes, as well as quality of life (QoL) and function in patients with ankle sarcomas undergoing three forms of surgical treatment, minor or major limb salvage surgery...

Impact of NICE guidelines on the survival of patients with soft-tissue sarcomas.
https://doi.org/10.1302/0301-620X.103B3.BJJ-2020-0743.R1
The Bone & Joint Journal; Fujiwara T, Grimer RJ et. al.

Mar 1st, 2021 - Urgent referral to a specialist centre for patients with a soft-tissue sarcoma (STS) has been recommended by the National Institute for Health and Care Excellence (NICE) in the UK since 2006. However, the impact of this recommendation on the progn...

Cardiac Tamponade as an Unusual Initial Clinical Manifestation of CIC-DUX4 Sarcoma.
https://doi.org/10.12659/AJCR.929349
The American Journal of Case Reports; Maekawa A, Matsunobu T et. al.

Feb 28th, 2021 - BACKGROUND CIC-rearranged sarcoma (CRS) is a recently described subset of undifferentiated small-round-cell sarcomas of bone and soft tissue. DUX4 is the most common gene involved in CRS. CRS usually presents in the soft tissue of the trunk and ex...

What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and...
https://doi.org/10.1097/CORR.0000000000001681
Clinical Orthopaedics and Related Research; Aryal A, Kumar VS et. al.

Feb 26th, 2021 - Skeletal metastases of bone sarcomas are indicators of poor prognosis. Various imaging modalities are available for their identification, which include bone scan, positron emission tomography/CT scan, MRI, and bone marrow aspiration/biopsy. Howeve...

Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherap...
https://doi.org/10.1007/s12094-021-02559-z 10.1200/JCO.2002.20.3.776 10.1200/JCO.2003.08.165 10.1158/1078-0432.CCR-16-2349 10.1002/cncr.30738 10.1016/s1470-2045(17)30624-1 10.1001/jamaoncol.2017.1617 10.1073/pnas.0915174107 10.1158/2159-8290.CD-17-1417 10.1002/cncr.30606 10.1007/s12094-012-0795-1 10.1158/1078-0432.CCR-15-2550 10.1200/JCO.2014.58.0225 10.1007/s00262-015-1731-3 10.1158/1078-0432.CCR-14-2708 10.2217/imt-2017-0101 10.1056/NEJMoa1802357 10.1200/JCO.2015.64.8931 10.1056/NEJMoa1504627 10.1016/s0140-6736(18)31257-1 10.1158/2159-8290.CD-17-0593 10.1038/s41591-018-0321-2 10.1158/1535-7163.MCT-14-0983 10.1038/nature14011 10.1001/jamaoncol.2016.0639 10.1371/journal.pone.0052926 10.21873/anticanres.12933 10.1111/cas.13769 10.1016/j.jtho.2019.06.010 10.1016/s1470-2045(13)70585-0 10.1200/JCO.2008.18.0794 10.1056/NEJMoa1708566 10.1056/NEJMoa1611299 10.1016/s1470-2045(19)30626-6 10.1016/s1567-5769(01)00071-6 10.1186/1479-5876-5-67 10.1007/s10549-004-3289-1 10.3109/08923970903300151 10.4049/jimmunol.175.3.1586 10.1158/1078-0432.CCR-11-2941 10.1186/1471-230X-12-109 10.1371/journal.pone.0082870 10.7150/jca.18683 10.1038/85330 10.3389/fonc.2019.00047 10.1016/j.oraloncology.2019.01.015 10.1245/s10434-019-07231-z 10.1111/j.1349-7006.2006.00317.x 10.1002/jso.21829 10.1080/2162402X.2016.1278100
Clinical & Translational Oncology : Official Publication ... Miwa S, Nojima T et. al.

Feb 26th, 2021 - Although immunotherapy is thought to be a promising cancer treatment, most patients do not respond to immunotherapy. In this post hoc analysis of a phase 1/2 study, associations of programmed death ligand 1 (PD-L1), PD-L2, and HLA class I expressi...

see more →

News  307 results

Fast Five Quiz: Thyroid Cancer Practice Essentials
https://reference.medscape.com/viewarticle/938275

Sep 30th, 2020 - Although benign thyroid disease is relatively common, thyroid cancer occurs far less frequently. Most thyroid cancers are papillary carcinomas, with follicular carcinomas, medullary thyroid carcinomas, and anaplastic carcinomas accounting for far ...

Pembrolizumab Shows Activity in Select Rare Sarcomas
https://www.staging.medscape.com/viewarticle/937967

Sep 23rd, 2020 - Sarcomas are rare malignancies, and effective therapies, apart from surgery and radiotherapy, are largely limited to chemotherapy and a handful of targeted agents. But a few rare sarcoma subtypes may respond to therapy with the immune checkpoint i...

Pembrolizumab Shows Activity in Select Rare Sarcomas
https://www.medscape.com/viewarticle/937967

Sep 23rd, 2020 - Sarcomas are rare malignancies, and effective therapies, apart from surgery and radiotherapy, are largely limited to chemotherapy and a handful of targeted agents. But a few rare sarcoma subtypes may respond to therapy with the immune checkpoint i...

Becoming the paradigm for clinical trial enrollment
https://www.mdedge.com/sarcomajournal/article/214255/becoming-paradigm-clinical-trial-enrollment
William D. Tap, MD

Dec 13th, 2019 - The previous issue of The Sarcoma Journal focused on findings from numerous clinical trials in sarcomas of various histologies presented at ASCO’s annual meeting. This issue features a study on enrollment issues that surround clinical trials in sa.

see more →

Patient Education  29 results see all →